Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 12/20 | 0.77 |
| ▸ | KDR | P35968 | 1/20 | 0.77 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.67 |
| ▸ | FLT3 | P36888 | 8/20 | 0.66 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.66 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.66 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.66 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.66 |
| ▸ | CSF1R | P07333 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13234850 | 0.87 | RAF1 (1.00) | RAF1KDRRIPK2FLT3MAPK13 | |
| SCHEMBL939254 | 0.86 | RAF1 (0.80) | RAF1KDRRIPK2FLT3MAPK13 | |
| SCHEMBL13946067 | 0.85 | RAF1 (0.82) | RAF1KDRRIPK2FLT3MAPK13 | |
| SCHEMBL667238 | 0.84 | RAF1 (1.00) | RAF1KDRRIPK2FLT3MAPK13 | |
| SCHEMBL938059 | 0.83 | RAF1 (0.78) | RAF1KDRRIPK2FLT3MAPK13 | |
| SCHEMBL668800 | 0.82 | RAF1 (1.00) | RAF1KDRRIPK2FLT3MAPK13 | |
| SCHEMBL16990706 | 0.81 | RAF1 (0.62) | RAF1KDRRIPK2FLT3MAPK13 | |
| SCHEMBL668459 | 0.81 | RAF1 (1.00) | RAF1KDRRIPK2FLT3MAPK13 | |
| SCHEMBL5576422 | 0.80 | RAF1 (0.83) | RAF1KDRRIPK2FLT3MAPK13 | |
| SCHEMBL13234769 | 0.80 | FLT3 (1.00) | RAF1FLT3MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | AMBIT BIOSCIENCES CORPORATION | 2010-07-08 | — | — | US | disclosed |
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | AMBIT BIOSCIENCES CORPORATION | 2010-07-08 | — | — | US | disclosed |
| US-7750160-B2 | Isoxazolyl urea derivatives as kinase modulators | AMBIT BIOSCIENCES CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750160-B2 | Isoxazolyl urea derivatives as kinase modulators | AMBIT BIOSCIENCES CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | ABL1, ABL2, BCR | RAF1 372/4885KDR 1094/4885RIPK2 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.